CERTAIN INFORMATION (INDICATED BY “[…***…]”) AND SCHEDULES HAVE BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OPTION, COLLABORATION AND LICENSE AGREEMENT...Option, Collaboration and License Agreement • February 28th, 2022 • BeiGene, Ltd. • Pharmaceutical preparations • New York
This OPTION, COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 19, 2021 (the “Execution Date”) by and between BeiGene Switzerland GmbH, a Swiss corporation (“BeiGene”), and Novartis Pharma AG, a Swiss corporation (“Novartis”). BeiGene and Novartis are each referred to herein by name, or as a “Party” or, collectively, as the “Parties.”
Option, Collaboration and License Agreement By And Between Novartis Pharma AG And Conatus Pharmaceuticals Inc.Option, Collaboration and License Agreement • March 16th, 2017 • Conatus Pharmaceuticals Inc. • Pharmaceutical preparations • New York
This OPTION, COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is made as of this 19 day of December, 2016 (“Execution Date”), by and between Novartis Pharma AG, a corporation organized and existing under the laws of Switzerland (“Novartis”) and Conatus Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of Delaware, U.S.A. (“Conatus”). Novartis and Conatus are each referred to individually as a “Party” and together as the “Parties.”
OPTION, COLLABORATION AND LICENSE AGREEMENTOption, Collaboration and License Agreement • May 11th, 2009 • Micromet, Inc. • Biological products, (no disgnostic substances)
This Option, Collaboration and License Agreement (the “Agreement”) is made and entered into effective as of January 12, 2009 (the “Effective Date”), by and between Micromet AG, having its principal place of business at Staffelseestrasse 2, 81477 Munich, Germany (“Micromet”), and Bayer Schering Pharma AG, having its principal place of business at Muellerstrasse 178, 13353 Berlin, Germany (“Bayer”). Micromet and Bayer each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
AMENDMENT TO OPTION, COLLABORATION AND LICENSE AGREEMENTOption, Collaboration and License Agreement • October 4th, 2019 • Conatus Pharmaceuticals Inc. • Pharmaceutical preparations • New York
This Amendment (“Amendment”) to the Option, Collaboration and License Agreement dated as of the 19th day of December, 2016 by and between Novartis Pharma AG, a corporation organized and existing under the laws of Switzerland (“Novartis”), and Conatus Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of Delaware, U.S.A. (“Conatus”), (the “Agreement”), is made and effective as of September 30th, 2019 (the “Amendment Effective Date”). Any capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Agreement.
